Mito-FLAG as salvage therapy for relapsed and refractory acute myeloid leukemia

Onkologie

Volumn 24, Issue 4, 2001, Pages 356-360

  Hanel M ^b   Friedrichsen, K ^a   Hanel A ^a   Herbst, R ^a   Morgner, A ^a   Neser, S ^a   Nicklisch, M ^a   Teich, M ^a   Ehninger, G ^b   Fiedler, F ^c  

^a KLINIKUM CHEMNITZ   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c NONE

Author keywords

Acute myeloid leukemia; Mito FLAG protocol; Salvage therapy

Indexed keywords

CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; LEUKOCYTE COUNT; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CYTARABINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; PILOT PROJECTS; SALVAGE THERAPY; SURVIVAL RATE; VIDARABINE;

EID: 18444380237     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055107     Document Type: Article

References (28)

1. Idarubicin and intermediate dose Ara-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia
2. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high risk acute myeloid leukemia: Results of an age-adjusted prospective randomized comparison
3. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience
4. A phase III trial of high dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia
5. Allogeneic hematopoietic stem cell transplantation for acute leukemia
6. Autologous stem cell transplantation in acute myelocytic leukemia
7. Treatment strategies in acute myelogenous leukemia (AML). B. Second-line treatment
8. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy
9. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia
10. Cell kinetic, molecular and clinical analysis of growth factor sensitization of myeloid leukemia
11. In vivo recombinant human G-CSF priming in previously untreated acute myeloid leukemia
12. Regulation of Bcl-2 expression and apoptosis in acute myeloblastic leukaemia cells by granulocyte-macrophage colony-stimulating factor
13. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte colony-stimulating factor during therapy of acute myelogenous leukemia
14. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia
15. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia
16. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia
17. Early allogeneic transplantation for refractory or relapsed leukaemia following remission induction with FLAG
18. Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation
19. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia
20. FLAG is a useful regimen for poor prognosis adult myeloid leukemias and myelodysplastic syndromes
21. Idarubicin, fludarabine, cytosine arabinoside and filgrastim (Ida-FLAG): A combination for treatment of refractory, relapsed and secondary AML
22. Mitoxantrone in the treatment of acute myelogenous leukemia: A review
23. Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide
24. Sequential administration of fludarabine, Ara-C and mitoxantrone enhances topoisomerase II-DNA complex formation and has efficacy in acute leukemia
25. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine
26. The effect of 9-β-D-arabinofuranosyl-2-fluoroadenine and 1-β-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells
27. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: Implications for a continuous infusion schedule
28. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British cooperative group